SLC5A2 and type 2 diabetes mellitus: One of the most promising areas of innovation involves the use of sodium–glucose cotransporter-2 (SGLT2) inhibitors, originally developed for type 2 diabetes, but now recognized for their robust cardioprotective properties [54].